Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QA102 in Dry Age-Related Macular Degeneration
NCT05536752Phase 2Completed
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QA102 in age-related macular degeneration (AMD). Started Sep 2022; status: completed.
02
Drugs
QA102
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05536752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536752.